Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc
Express News | Pliant Therapeutics Appoints Gary Palmer, M.d. as Senior Vice President of Medical Affairs
Express News | Pliant Therapeutics Inc - Grants 120,000 Stock Options to New Svp Gary Palmer
Express News | Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Does Pliant Therapeutics (NASDAQ:PLRX) Have A Healthy Balance Sheet?
Express News | Aligos Therapeutics Strengthens Senior Leadership Team With the Appointment of Hardean Achneck, Md as Chief Medical Officer
Piper Sandler Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $40
Piper Sandler analyst Yasmeen Rahimi maintains $Pliant Therapeutics(PLRX.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 39.
Pliant Therapeutics (PLRX) Gets a Buy From Piper Sandler
Bullish on Bexo: Pliant Therapeutics' Promising IPF Treatment Backed by Strong Clinical Evidence
Pliant Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.
H.C. Wainwright Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $38
H.C. Wainwright analyst Ed Arce maintains $Pliant Therapeutics(PLRX.US)$ with a buy rating, and maintains the target price at $38.According to TipRanks data, the analyst has a success rate of 42.7%
Buy Rating Affirmed for Pliant Therapeutics on Strong Bexotegrast Clinical Data and Broad Therapeutic Potential
Leerink Partners Initiates Pliant Therapeutics(PLRX.US) With Buy Rating, Announces Target Price $33
Leerink Partners analyst Faisal Khurshid initiates coverage on $Pliant Therapeutics(PLRX.US)$ with a buy rating, and sets the target price at $33.According to TipRanks data, the analyst has a
Express News | Pliant Therapeutics Inc : Leerink Partners Assumes Coverage With Outperform Rating; Target Price $33
Oppenheimer Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $45
Oppenheimer analyst Jeff Jones maintains $Pliant Therapeutics(PLRX.US)$ with a buy rating, and maintains the target price at $45.According to TipRanks data, the analyst has a success rate of 42.9%
Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
Pliant Therapeutics Announces 4 Upcoming Presentations At The ERS International Congress 2024
CCORF Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $43
CCORF analyst Edward Nash maintains $Pliant Therapeutics(PLRX.US)$ with a buy rating, and maintains the target price at $43.According to TipRanks data, the analyst has a success rate of 41.9% and a
HC Wainwright & Co. Maintains Buy on Pliant Therapeutics, Raises Price Target to $38
Pliant Therapeutics Analyst Ratings